trial

A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia

NCTId NCT07225712
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Recruiting
Enrollment 100 (estimated)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2028-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Recruiting
Enrollment
100 (estimated)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2025-12-22
Primary completion
2028-03
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Ulotaront

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Investigators

1
Nobuhito SanadaStudy Director

Sites

1 total
Fukuoka, Japan

Linked catalysts

1
A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia — primary completion2028-03

Facts & assertions

4 sourced
Enrollment
100
Phase
PHASE3
Primary Completion Date
2028-03
Status
RECRUITING
relationships
The graph out of here
drug
Ulotaront
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Nobuhito Sanada
person